People · Operator
Named in public records as an officer, director or promoter · active 2016–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Aprea Therapeutics, Inc. | — | Biotechnology | Seed | $3.1M | $6.7M | 2025 |
| Atrin Pharmaceuticals LLC | — | Biotechnology | Seed | $2.7M | $66.6M | 2016 |
Oren Gilad at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Oren Gilad on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| John B. Henneman | 1 | 2 |
| John P. Hamill | 1 | 2 |
| Bernard C Rudnick | 1 | 2 |
| Rifat B. Pamukcu | 1 | 1 |
| Bernd B. Seizinger | 1 | 1 |
| Marc P. Duey | 1 | 1 |
| Michael P. Grissinger | 1 | 1 |
| Richard P. Peters | 1 | 1 |
| Jean-Pierre P. Bizzari | 1 | 1 |
| Gabriela P. Gruia | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.